Ez detect colon disease test reviews năm 2024

Purpose: Colorectal cancer (CRC) screening with fecal occult blood testing (FOBT) has been associated with a reduction in CRC incidence and CRC-related mortality. However, a conventional FOBT requires stool collection and handling, which may be inconvenient for participants. The EZ-DetectTM (Siam Pharmaceutical Thailand) is a FDA-approved chromogen-substrate based FOBT which is basically a self-checked FOBT (no stool handling required). This study aimed to evaluate the accuracy of EZ-Detect for CRC detection.

Methods: This prospective study was conducted in the Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand between November 2013 and May 2014. Some 96 patients with histologically-proven CRC and 101 patients with normal colonoscopic findings were invited to perform self-checked FOBT according to the manufacturer's instructions. RESULTS were compared with endoscopic and pathologic findings. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for CRC detection were calculated.

Results: The present study revealed the sensitivity, specificity, PPV and NPV of this self-checked FOBT for CRC detection to be 41% (95% CI: 31-51), 97% (95% CI: 92-99), 93% (95% CI: 81-98) and 63% (95% CI: 55-70), respectively. The overall accuracy of the self-checked FOBT for identifying CRC was 70%. The sensitivity for CRC detection based on 7th AJCC staging was 29% for stage I, 32% for stage II and 50% for stage III/IV (P=0.19). The sensitivity was 33% for proximal colon and 42% for distal colon and rectal cancer (P=0.76). Notably, none of nine infiltrative lesions gave a positive FOBT.

Conclusions: The self-checked FOBT had an acceptable accuracy of CRC detection except for infiltrative tumors. This home-administrated or 'DIY' do-it-yourself FOBT could be considered as one non-invasive and convenient tool for CRC screening.

PubMed Disclaimer

Similar articles

  • Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test. Dollinger MM, Behl S, Fleig WE. Dollinger MM, et al. Clin Lab. 2018 Oct 1;64(10):1719-1730. doi: 10.7754/Clin.Lab.2018.180521. Clin Lab. 2018. PMID: 30336540
  • A multicenter prospective study of immunochemical fecal occult blood testing for colorectal cancer detection. Lohsiriwat V, Thavichaigarn P, Awapittaya B. Lohsiriwat V, et al. J Med Assoc Thai. 2007 Nov;90(11):2291-5. J Med Assoc Thai. 2007. PMID: 18181309
  • Systematic review with meta-analysis: faecal occult blood tests show lower colorectal cancer detection rates in the proximal colon in colonoscopy-verified diagnostic studies. Hirai HW, Tsoi KK, Chan JY, Wong SH, Ching JY, Wong MC, Wu JC, Chan FK, Sung JJ, Ng SC. Hirai HW, et al. Aliment Pharmacol Ther. 2016 Apr;43(7):755-64. doi: 10.1111/apt.13556. Epub 2016 Feb 9. Aliment Pharmacol Ther. 2016. PMID: 26858128 Review.
  • Results of National Colorectal Cancer Screening Program in Croatia (2007-2011). Katičić M, Antoljak N, Kujundžić M, Stamenić V, Skoko Poljak D, Kramarić D, Stimac D, Strnad Pešikan M, Samija M, Ebling Z. Katičić M, et al. World J Gastroenterol. 2012 Aug 28;18(32):4300-7. doi: 10.3748/wjg.v18.i32.4300. World J Gastroenterol. 2012. PMID: 22969192 Free PMC article.
  • Screening for Colorectal Cancer: An Updated Systematic Review [Internet]. Whitlock EP, Lin J, Liles E, Beil T, Fu R, O'Connor E, Thompson RN, Cardenas T. Whitlock EP, et al. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Oct. Report No.: 08-05-05124-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Oct. Report No.: 08-05-05124-EF-1. PMID: 20722162 Free Books & Documents. Review.

Cited by

  • Comprehensive functional genomic analyses link APC somatic mutation and mRNA-miRNA networks to the clinical outcome of stage-III colorectal cancer patients. Chiang SF, Huang HH, Tsai WS, Chin-Ming Tan B, Yang CY, Huang PJ, Yi-Feng Chang I, Lin J, Lu PS, Chin E, Liu YH, Yu JS, Chiang JM, Hung HY, You JF, Liu H. Chiang SF, et al. Biomed J. 2022 Apr;45(2):347-360. doi: 10.1016/j.bj.2021.03.001. Epub 2021 Mar 16. Biomed J. 2022. PMID: 35550340 Free PMC article.
  • Dysbiosis of human gut microbiome in young-onset colorectal cancer. Yang Y, Du L, Shi D, Kong C, Liu J, Liu G, Li X, Ma Y. Yang Y, et al. Nat Commun. 2021 Nov 19;12(1):6757. doi: 10.1038/s41467-021-27112-y. Nat Commun. 2021. PMID: 34799562 Free PMC article.
  • Diagnostic Accuracy of FOBT and Colorectal Cancer Genetic Testing: A Systematic Review & Meta-Analysis. Ramdzan AR, Abd Rahim MA, Mohamad Zaki A, Zaidun Z, Mohammed Nawi A. Ramdzan AR, et al. Ann Glob Health. 2019 May 15;85(1):70. doi: 10.5334/aogh.2466. Ann Glob Health. 2019. PMID: 31099505 Free PMC article.

High prevalence of advanced colorectal neoplasia in the Thai population: a prospective screening colonoscopy of 1,404 cases.

Siripongpreeda B, Mahidol C, Dusitanond N, Sriprayoon T, Muyphuag B, Sricharunrat T, Teerayatanakul N, Chaiwong W, Worasawate W, Sattayarungsee P, Sangthongdee J, Prarom J, Sornsamdang G, Soonklang K, Wittayasak K, Auewarakul CU.

How accurate is EZ Detect?

Most studies suggest that only 5 to 10 percent of those with positive test results will be diagnosed as having cancer. However, it is imperative that anyone with a positive test result see a physician as soon as possible to determine the cause of the bleeding.

How does EZ detect colon disease test work?

EZ Detect™ is a simple, sanitary, fast home test requiring no stool handling. The user simply drops a test tissue into the toilet bowl, and if blood is present, a blue-green color will appear within two minutes. Physicians, hospitals, and pharmacies utilize the test.

How accurate is stool test for colon cancer?

The sensitivity of detection of carcinoma is a remarkably acceptable comparison. The multi-targeted stool DNA test is 92% sensitive for finding cancers, which is almost equal to colonoscopy, reportedly at 95%.

What is the new test for colon cancer?

At a time when colorectal cancer is on the rise, a new study finds the disease can be detected through a blood test. The results of a clinical trial, published Wednesday, in The New England Journal of Medicine, show that the blood-based screening test detects 83% of people with colorectal cancer.